(Bloomberg) -- Novavax ... vaccine at its own cost. Shares of Sanofi rose slightly in early trading in Paris. The stock was down about 5% in the past 12 months through Thursday’s close. The deal ...
Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.
Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up to $1.2 billion.
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...
The top-three investor in Novavax ... malaria vaccine – which uses its Matrix-M adjuvant – had been shipped by partner Serum Institute of India to Africa. The deal with Sanofi includes ...
Gaithersburg, Maryland-based Novavax received ... it struck a $1.2 billion licensing agreement with French drugmaker Sanofi to co-commercialize the combination vaccine. Get breaking news and ...
PR Newswire • 16 days ago Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized ... Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value ...
Sanofi, RadioMedix and Orano Med have entered into an exclusive licensing agreement worth €320m to develop a next-generation ...
Novavax (NASDAQ:NVAX), Sanofi (NASDAQ:SNY) – Novavax closed a $1.4 billion deal with Sanofi to commercialize its Covid-19 vaccine and ... it aims to close data licensing deals and explore ...